;PMID: 11199127
;source_file_1909.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)sentence:[e:39..176] = [t:39..176]
;2)section:[e:180..276] = [t:180..276]
;3)section:[e:280..375] = [t:280..375]
;4)sentence:[e:379..558] = [t:379..558]
;5)sentence:[e:559..710] = [t:559..710]
;6)sentence:[e:711..826] = [t:711..826]
;7)sentence:[e:827..1002] = [t:827..1002]
;8)sentence:[e:1003..1182] = [t:1003..1182]
;9)sentence:[e:1183..1285] = [t:1183..1285]
;10)sentence:[e:1286..1441] = [t:1286..1441]
;11)section:[e:1445..1490] = [t:1445..1490]

;section 0 Span:0..33
;Planta Med. 2000 Dec;66(8):714-9.
(SEC
  (FRAG (NNP:[0..6] Planta) (NNP:[7..10] Med) (.:[10..11] .) (CD:[12..16] 2000)
        (CC:[17..24] Dec;66-LRB-) (CD:[24..25] 8) (-RRB-:[25..26] -RRB-)
        (::[26..27] :) (CD:[27..30] 714) (::[30..31] -) (CD:[31..33] 9.)))

;sentence 1 Span:39..176
;Panax vietnamensis protects mice against carbon tetrachloride-induced 
;hepatotoxicity without any modification of CYP2E1 gene expression.
;[39..57]:substance:"Panax vietnamensis"
;[80..100]:substance:"carbon tetrachloride"
(SENT
  (S-HLN
    (NP-SBJ (NN:[39..44] Panax) (NN:[45..57] vietnamensis))
    (VP (NNS:[58..66] protects)
      (NP (NNS:[67..71] mice))
      (PP-CLR (IN:[72..79] against)
        (NP
          (ADJP
            (NML (NN:[80..86] carbon) (NN:[87..100] tetrachloride))
            (HYPH:[100..101] -) (VBN:[101..108] induced))
          (NN:[110..124] hepatotoxicity)))
      (PP (IN:[125..132] without)
        (NP
          (NP (DT:[133..136] any) (NN:[137..149] modification))
          (PP (IN:[150..152] of)
            (NP (NN:[153..159] CYP2E1) (NN:[160..164] gene)
                (NN:[165..175] expression))))))
    (.:[175..176] .)))

;section 2 Span:180..276
;Nguyen TD, Villard PH, Barlatier A, Elsisi AE, Jouve E, Duc NM, Sauze C,
;Durand  A, Lacarelle B.
(SEC
  (FRAG (NNP:[180..186] Nguyen) (NN:[187..189] TD) (,:[189..190] ,)
        (NNP:[191..198] Villard) (NNP:[199..201] PH) (,:[201..202] ,)
        (NNP:[203..212] Barlatier) (NNP:[213..214] A) (,:[214..215] ,)
        (NNP:[216..222] Elsisi) (NNP:[223..225] AE) (,:[225..226] ,)
        (NNP:[227..232] Jouve) (NNP:[233..234] E) (,:[234..235] ,)
        (NNP:[236..239] Duc) (NNP:[240..242] NM) (,:[242..243] ,)
        (NNP:[244..249] Sauze) (NNP:[250..251] C) (,:[251..252] ,)
        (NNP:[253..259] Durand) (NNP:[261..262] A) (,:[262..263] ,)
        (NNP:[264..273] Lacarelle) (NNP:[274..276] B.)))

;section 3 Span:280..375
;Laboratory of Toxicology (EA2194), School of Pharmacy, Univ. Mediterranee, 
;Marseilles, France.
(SEC
  (FRAG (NNP:[280..290] Laboratory) (IN:[291..293] of)
        (NNP:[294..304] Toxicology) (-LRB-:[305..306] -LRB-)
        (NN:[306..312] EA2194) (-RRB-:[312..313] -RRB-) (,:[313..314] ,)
        (NNP:[315..321] School) (IN:[322..324] of) (NNP:[325..333] Pharmacy)
        (,:[333..334] ,) (NNP:[335..339] Univ) (.:[339..340] .)
        (NNP:[341..353] Mediterranee) (,:[353..354] ,)
        (NNP:[356..366] Marseilles) (,:[366..367] ,) (NNP:[368..374] France)
        (.:[374..375] .)))

;sentence 4 Span:379..558
;In order to explore the effect of Panax vietnamensis on carbon 
;tetrachloride-induced hepatotoxicity, mice were pretreated for 7 days with 
;either crude extract or total saponins.
;[413..431]:substance:"Panax vietnamensis"
;[435..456]:substance:"carbon  tetrachloride"
;[506..507]:quantitative-value:"7"
;[508..512]:quantitative-units:"days"
;[526..539]:substance:"crude extract"
;[549..557]:substance:"saponins"
(SENT
  (S
    (SBAR-PRP (IN:[379..381] In) (NN:[382..387] order)
      (S
        (NP-SBJ (-NONE-:[387..387] *))
        (VP (TO:[388..390] to)
          (NP (VB:[391..398] explore)
            (NP
              (NP (DT:[399..402] the) (NN:[403..409] effect))
              (PP (IN:[410..412] of)
                (NP (NN:[413..418] Panax) (NN:[419..431] vietnamensis))))
            (PP (IN:[432..434] on)
              (NP
                (ADJP
                  (NML (NN:[435..441] carbon) (NN:[443..456] tetrachloride))
                  (HYPH:[456..457] -) (VBN:[457..464] induced))
                (NN:[465..479] hepatotoxicity)))))))
    (,:[479..480] ,)
    (NP-SBJ-1 (NNS:[481..485] mice))
    (VP (VBD:[486..490] were)
      (VP (VBN:[491..501] pretreated)
        (NP-1 (-NONE-:[501..501] *))
        (PP-TMP (IN:[502..505] for)
          (NP (CD:[506..507] 7) (NNS:[508..512] days)))
        (PP (IN:[513..517] with)
          (NP (CC:[519..525] either)
            (NP (JJ:[526..531] crude) (NN:[532..539] extract))
            (CC:[540..542] or)
            (NP (JJ:[543..548] total) (NNS:[549..557] saponins))))))
    (.:[557..558] .)))

;sentence 5 Span:559..710
;Crude extract and total saponins  dramatically decreased carbon
;tetrachloride-induced increase of serum GST alpha  level (-50.0%, -49.5%
;respectively).
;[559..572]:substance:"Crude extract"
;[583..591]:substance:"saponins"
;[616..636]:substance:"carbon tetrachloride"
;[663..672]:substance:"GST alpha"
;[681..687]:quantitative-value:"-50.0%"
;[689..695]:quantitative-value:"-49.5%"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[559..564] Crude) (NN:[565..572] extract))
      (CC:[573..576] and)
      (NP (JJ:[577..582] total) (NNS:[583..591] saponins)))
    (ADVP (RB:[593..605] dramatically))
    (VP (VBD:[606..615] decreased)
      (NP
        (NP
          (ADJP
            (NML (NN:[616..622] carbon) (NN:[623..636] tetrachloride))
            (HYPH:[636..637] -) (VBN:[637..644] induced))
          (NN:[645..653] increase))
        (PP (IN:[654..656] of)
          (NP (NN:[657..662] serum)
            (NML (NN:[663..666] GST) (SYM:[667..672] alpha))
            (NN:[674..679] level))))
      (PRN (-LRB-:[680..681] -LRB-)
        (FRAG
          (NP
            (QP (SYM:[681..682] -) (CD:[682..686] 50.0))
            (NN:[686..687] %))
          (,:[687..688] ,)
          (NP
            (QP (SYM:[689..690] -) (CD:[690..694] 49.5))
            (NN:[694..695] %))
          (ADVP (RB:[696..708] respectively)))
        (-RRB-:[708..709] -RRB-)))
    (.:[709..710] .)))

;sentence 6 Span:711..826
;Serum AST level was significantly decreased  only with total saponins
;(-52.2%) and ALT level was slightly modified.
;[717..720]:substance:"AST"
;[772..780]:substance:"saponins"
;[782..788]:quantitative-value:"-52.2%"
;[794..797]:substance:"ALT"
(SENT
  (S
    (S
      (NP-SBJ-2 (NN:[711..716] Serum) (NN:[717..720] AST) (NN:[721..726] level))
      (VP (VBD:[727..730] was)
        (ADVP (RB:[731..744] significantly))
        (VP (VBN:[745..754] decreased)
          (NP-2 (-NONE-:[754..754] *))
          (PP (RB:[756..760] only) (IN:[761..765] with)
            (NP
              (NP (JJ:[766..771] total) (NNS:[772..780] saponins))
              (PRN (-LRB-:[781..782] -LRB-)
                (NP
                  (QP (SYM:[782..783] -) (CD:[783..787] 52.2))
                  (NN:[787..788] %))
                (-RRB-:[788..789] -RRB-)))))))
    (CC:[790..793] and)
    (S
      (NP-SBJ-1 (NN:[794..797] ALT) (NN:[798..803] level))
      (VP (VBD:[804..807] was)
        (ADVP (RB:[808..816] slightly))
        (VP (VBN:[817..825] modified)
          (NP-1 (-NONE-:[825..825] *)))))
    (.:[825..826] .)))

;sentence 7 Span:827..1002
;In vitro  experiments shown that both preparations at high concentrations (>
;2000  micrograms/ml) are able to inhibit CYP2E1 enzymatic activity in mouse
;and human  microsomes.
;[902..908]:quantitative-value:"> 2000"
;[910..923]:quantitative-units:"micrograms/ml"
;[945..951]:cyp450:"CYP2E1"
(SENT
  (S
    (NP-SBJ
      (ADJP (FW:[827..829] In) (FW:[830..835] vitro))
      (NNS:[837..848] experiments))
    (VP (VBN:[849..854] shown)
      (SBAR (IN:[855..859] that)
        (S
          (NP-SBJ
            (NP (DT:[860..864] both) (NNS:[865..877] preparations))
            (PP (IN:[878..880] at)
              (NP (JJ:[881..885] high) (NNS:[886..900] concentrations)
                (PRN (-LRB-:[901..902] -LRB-)
                  (ADJP (SYM:[902..903] >)
                    (NP
                      (NP (CD:[904..908] 2000) (NNS:[910..920] micrograms))
                      (PP (SYM:[920..921] /)
                        (NP (NN:[921..923] ml)))))
                  (-RRB-:[923..924] -RRB-)))))
          (VP (VBP:[925..928] are)
            (ADJP-PRD (JJ:[929..933] able)
              (S
                (NP-SBJ (-NONE-:[933..933] *))
                (VP (TO:[934..936] to)
                  (VP (VB:[937..944] inhibit)
                    (NP (NN:[945..951] CYP2E1) (JJ:[952..961] enzymatic)
                        (NN:[962..970] activity))
                    (PP-LOC (IN:[971..973] in)
                      (NP
                        (NP (NN:[974..979] mouse)
                          (NML-1 (-NONE-:[979..979] *P*)))
                        (CC:[980..983] and)
                        (NP (JJ:[984..989] human)
                          (NML-1 (NNS:[991..1001] microsomes)))))))))))))
    (.:[1001..1002] .)))

;sentence 8 Span:1003..1182
;However, we did not observe any modification of Cyp2e1 gene  expression
;(enzymatic activity, protein and mRNA levels) in mice treated with  either
;crude extract or total saponins.
;[1096..1103]:cyp450:"protein"
;[1108..1112]:substance:"mRNA"
;[1150..1163]:substance:"crude extract"
;[1173..1181]:substance:"saponins"
(SENT
  (S
    (ADVP (RB:[1003..1010] However))
    (,:[1010..1011] ,)
    (NP-SBJ (PRP:[1012..1014] we))
    (VP (VBD:[1015..1018] did) (RB:[1019..1022] not)
      (VP (VB:[1023..1030] observe)
        (NP
          (NP (DT:[1031..1034] any) (NN:[1035..1047] modification))
          (PP (IN:[1048..1050] of)
            (NP (NN:[1051..1057] Cyp2e1) (NN:[1058..1062] gene)
                (NN:[1064..1074] expression)))
          (PRN (-LRB-:[1075..1076] -LRB-)
            (NP
              (NP (JJ:[1076..1085] enzymatic) (NN:[1086..1094] activity))
              (,:[1094..1095] ,)
              (NP
                (NP (NN:[1096..1103] protein)
                  (NML-1 (-NONE-:[1103..1103] *P*)))
                (CC:[1104..1107] and)
                (NP (NN:[1108..1112] mRNA)
                  (NML-1 (NNS:[1113..1119] levels)))))
            (-RRB-:[1119..1120] -RRB-)))
        (PP-LOC (IN:[1121..1123] in)
          (NP
            (NP (NNS:[1124..1128] mice))
            (VP (VBN:[1129..1136] treated)
              (NP (-NONE-:[1136..1136] *))
              (PP-MNR (IN:[1137..1141] with)
                (NP (CC:[1143..1149] either)
                  (NP (JJ:[1150..1155] crude) (NN:[1156..1163] extract))
                  (CC:[1164..1166] or)
                  (NP (JJ:[1167..1172] total) (NNS:[1173..1181] saponins)))))))))
    (.:[1181..1182] .)))

;sentence 9 Span:1183..1285
;Taken together, these data demonstrated  that Panax vietnamensis could be
;used as an hepatoprotectant.
;[1229..1247]:substance:"Panax vietnamensis"
;[1268..1284]:substance:"hepatoprotectant"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[1183..1183] *))
      (VP (VBN:[1183..1188] Taken)
        (ADVP (RB:[1189..1197] together))))
    (,:[1197..1198] ,)
    (NP-SBJ (DT:[1199..1204] these) (NNS:[1205..1209] data))
    (VP (VBD:[1210..1222] demonstrated)
      (SBAR (IN:[1224..1228] that)
        (S
          (NP-SBJ-1 (NN:[1229..1234] Panax) (NN:[1235..1247] vietnamensis))
          (VP (MD:[1248..1253] could)
            (VP (VB:[1254..1256] be)
              (VP (VBN:[1257..1261] used)
                (NP-1 (-NONE-:[1261..1261] *))
                (PP-MNR (IN:[1262..1264] as)
                  (NP (DT:[1265..1267] an) (NN:[1268..1284] hepatoprotectant)))))))))
    (.:[1284..1285] .)))

;sentence 10 Span:1286..1441
;However, the  mechanism of action is not associated with CYP2E1 expression,
;as previously  suggested in vitro in rat for total saponins from Panax
;ginseng.
;[1343..1349]:cyp450:"CYP2E1"
;[1413..1421]:substance:"saponins"
;[1427..1440]:substance:"Panax ginseng"
(SENT
  (S
    (ADVP (RB:[1286..1293] However))
    (,:[1293..1294] ,)
    (NP-SBJ-1
      (NP (DT:[1295..1298] the) (NN:[1300..1309] mechanism))
      (PP (IN:[1310..1312] of)
        (NP (NN:[1313..1319] action))))
    (VP (VBZ:[1320..1322] is) (RB:[1323..1326] not)
      (VP (VBN:[1327..1337] associated)
        (NP-1 (-NONE-:[1337..1337] *))
        (PP-CLR (IN:[1338..1342] with)
          (NP (NN:[1343..1349] CYP2E1) (NN:[1350..1360] expression)))
        (,:[1360..1361] ,)
        (PP (IN:[1362..1364] as)
          (S-NOM
            (NP-SBJ-2 (-NONE-:[1364..1364] *))
            (ADVP (RB:[1365..1375] previously))
            (VP (VBN:[1377..1386] suggested)
              (NP-2 (-NONE-:[1386..1386] *))
              (ADVP (FW:[1387..1389] in) (FW:[1390..1395] vitro))
              (PP-LOC (IN:[1396..1398] in)
                (NP (NN:[1399..1402] rat)))
              (PP (IN:[1403..1406] for)
                (NP
                  (NP (JJ:[1407..1412] total) (NNS:[1413..1421] saponins))
                  (PP (IN:[1422..1426] from)
                    (NP (NN:[1427..1432] Panax) (NN:[1433..1440] ginseng))))))))))
    (.:[1440..1441] .)))

;section 11 Span:1445..1490
;PMID: 11199127 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1445..1449] PMID) (::[1449..1450] :) (CD:[1451..1459] 11199127)
        (NN:[1460..1461] -LSB-) (NNP:[1461..1467] PubMed) (::[1468..1469] -)
        (NN:[1470..1477] indexed) (IN:[1478..1481] for)
        (NNP:[1482..1490] MEDLINE-RSB-)))
